Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov
Ilia N
IN
Department of Human Oncology, University of Wisconsin, Madison, WI 53705-2275, USA.
Sondel
Paul M
PM
Wigginton
Jon M
JM
Buhtoiarova
Tatiana N
TN
Yanke
Eric M
EM
Mahvi
David A
DA
Rakhmilevich
Alexander L
AL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019013:CD40 Antigens / Q000276:immunology; D045744:Cell Line, Tumor; D004357:Drug Synergism; D007167:Immunotherapy / Q000379:methods*; D008264:Macrophages / Q000166:cytology / Q000276:immunology*; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000166:cytology / Q000276:immunology; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy*; D009447:Neuroblastoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019013:CD40 Antigens; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides